StockNews.com initiated coverage on shares of Novavax (NASDAQ:NVAX – Get Rating) in a research note issued to investors on Thursday morning. The firm issued a sell rating on the biopharmaceutical company’s stock.
Other equities analysts have also recently issued research reports about the stock. B. Riley cut shares of Novavax from a buy rating to a neutral rating in a research note on Wednesday, March 1st. Jefferies Financial Group initiated coverage on shares of Novavax in a research note on Friday, December 2nd. They set a hold rating for the company. Finally, HC Wainwright reaffirmed a buy rating and set a $110.00 price objective on shares of Novavax in a research note on Monday, February 13th. Three research analysts have rated the stock with a sell rating, two have assigned a hold rating and two have issued a buy rating to the company. Based on data from MarketBeat, the stock presently has an average rating of Hold and an average price target of $76.29.
Novavax Trading Down 0.3 %
NVAX opened at $5.95 on Thursday. The firm has a 50-day moving average price of $9.74 and a 200-day moving average price of $16.13. Novavax has a twelve month low of $5.68 and a twelve month high of $85.60.
Hedge Funds Weigh In On Novavax
A number of hedge funds and other institutional investors have recently bought and sold shares of NVAX. Neo Ivy Capital Management purchased a new position in Novavax in the 3rd quarter worth approximately $37,000. Money Concepts Capital Corp bought a new stake in shares of Novavax in the 4th quarter worth approximately $37,000. CI Investments Inc. lifted its holdings in shares of Novavax by 1,572.8% in the 4th quarter. CI Investments Inc. now owns 3,747 shares of the biopharmaceutical company’s stock worth $39,000 after acquiring an additional 3,523 shares during the last quarter. Credit Agricole S A lifted its holdings in shares of Novavax by 65.8% in the 3rd quarter. Credit Agricole S A now owns 2,520 shares of the biopharmaceutical company’s stock worth $46,000 after acquiring an additional 1,000 shares during the last quarter. Finally, IFP Advisors Inc lifted its holdings in shares of Novavax by 328.3% in the 4th quarter. IFP Advisors Inc now owns 6,994 shares of the biopharmaceutical company’s stock worth $52,000 after acquiring an additional 5,361 shares during the last quarter. Hedge funds and other institutional investors own 45.70% of the company’s stock.
Novavax, Inc Is a biotechnology company, which engages in the discovery, development, and commercialization of recombinant vaccines. The company was founded in 1987 and is headquartered in Gaithersburg, MD.
- Get a free copy of the StockNews.com research report on Novavax (NVAX)
- MarketBeat Week in Review – 3/13 – 3/17
- This Small Tech With Big Growth Prospects Is Nearing A Buy Point
- Don’t Chase FedEx Higher, Wait For The Pullback
- 3 Stocks For A Defensive Tech Portfolio
- Milk the Dividends on These 3 Cash Cows
Receive News & Ratings for Novavax Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novavax and related companies with MarketBeat.com's FREE daily email newsletter.